We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Study Confirms Value of the MyProstateScore Urine Test for Prostate Cancer Screening

By LabMedica International staff writers
Posted on 22 Feb 2021
A recent paper confirmed that the MyProstateScore test could be used with confidence to detect clinically significant (grade group higher than 2) prostate cancers when compared to commonly used prostate specific antigen-based diagnostic screening.

Screening for prostate cancer generally relies on the serum prostate-specific antigen (PSA) test, which unfortunately generates a high rate of false positive results (up to 80%). More...
This generates a large number of unnecessary biopsies with resultant unpleasant side effects, such as bleeding and pain. Considering how often the PSA test is used, there is a critical unmet need for a precision screening method for diagnosis of prostate cancer.

To meet this need, the MyProstateScore test has been commercialized by the biotech company LynxDX (Ann Arbor, MI, USA). The MyProstateScore test measures levels of cancer-specific genes in a patient's urine. Specifically, it quantifies serum prostate specific antigen, urinary prostate cancer antigen 3, and urinary TMPRSS2:ERG, which is the relocation of the TMPRSS2 and ERG genes onto the same chromosome - a genetic anomaly found in nearly half of all prostate tumors.

In the current study, investigators at the University of Michigan (Ann Arbor, USA) used the MyProstateScore test to evaluate urine samples from 1,525 patients seen at academic health centers and in community health settings. Among these patients, 338 (22%) had cancers detected on biopsy that were group grade 2 or higher.

Results revealed that a MyProstateScore threshold of 10 provided 97% sensitivity and 98% negative predictive value for grade group higher than 2 cancer. MyProstateScore testing would have prevented 387 unnecessary biopsies (33%), while missing only 10 grade group higher than 2 cancers (3.0%). In 1,242 patients meeting guideline based criteria, a MyProstateScore of less than 10 provided 96% sensitivity and 97% negative predictive value, and would have prevented 32% of unnecessary biopsies, missing only 3.7% of grade group greater than 2 cancers.

"Our ultimate goal was to determine whether the MyProstateScore test could be a practical, reliable test that could rule out the need for more costly or invasive testing in men referred for a prostate biopsy," said senior author Dr. Jeffrey Tosoian, clinical lecturer in urology at the University of Michigan. "The data show that this straightforward, secondary testing approach could reduce the use of more costly and invasive procedures following a PSA test."

The paper was published in the March 1, 2021, online edition of the Journal of Urology.

Related Links:
University of Michigan
LynxDX



Gold Member
Serological Pipets
INTEGRA Serological Pipets
Portable Electronic Pipette
Mini 96
New
Laboratory Software
ArtelWare
New
Anterior Nasal Specimen Collection Swabs
53-1195-TFS, 53-0100-TFS, 53-0101-TFS, 53-4582-TFS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Pathology

view channel
Image: An adult fibrosarcoma case report has shown the importance of early diagnosis and targeted therapy (Photo courtesy of Sultana and Sailaja/Oncoscience)

Accurate Pathological Analysis Improves Treatment Outcomes for Adult Fibrosarcoma

Adult fibrosarcoma is a rare and highly aggressive malignancy that develops in connective tissue and often affects the limbs, trunk, or head and neck region. Diagnosis is complex because tumors can mimic... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.